Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 597-603

  Niizuma, Shinichiro ^a,b   Iwanaga, Yoshitaka ^a,b,c   Yahata, Takaharu ^a   Goto, Yoichi ^a   Kita, Toru ^b   Miyazaki, Shunichi ^a,c   Nakahama, Hajime ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BNP; Coronary artery disease; Haemodialysis; Left ventricular diastolic wall stress

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY HEMODYNAMICS; DISEASE ACTIVITY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE WALL MOTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HEMODYNAMICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NATRIURETIC PEPTIDE, BRAIN; RENAL DIALYSIS; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 58449097070     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn491     Document Type: Article

References (35)

1. Villar E, Remontet L, Labeeuw M et al. Effect of age, gender, and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol 2007; 18: 2125-2134
2. U.S. Renal Data System.: Atlas of End-Stage Renal Disease in the United States. USRDS 2004 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 2004
3. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163-167
4. Lindner A, Charre B, Sherrard DJ et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
5. Rostand SG, Gretes JC, Kirk KA et al. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 1979; 16: 600-611
6. Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocytehypertrophy; evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280-1287
7. Iwanaga Y, Nishi I, Furuichi S et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47: 742-748
8. Morrow DA, de Lemos JA, Blazing MA et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005; 294: 2866-2871
9. Konstam MA. Natriuretic peptides and cardiovascular events: more than a stretch. JAMA 2007; 297: 212-214
10. Goetze JP, Christoffersen C, Perko M. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17: 1105-1107
11. Bibbins-Domingo K, Ansari M, Sciller NB. B-type natriuretic peptide and ischemia in patients with stable coronary artery disease: data from the Heart and Soul study. Circulation 2003; 108: 2987-2992
12. Bibbins-Domingo K, Gupta R, Na B et al. N-Terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007; 297: 169-176
13. Weber M, Dill T, Arnold R et al. N-Terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004; 148: 612-620
14. Ishizaka Y, Yamamoto Y, Fukunaga T et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis 1994; 24: 461-472
15. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003; 4(Suppl 4): S13-S19
16. Naganuma T, Sugimura K, Wada S et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22: 437-444
17. Zoccali C, Mallamaci F, Benedetto FA et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12:1508-1515
18. Wang AY, Lam CW, Yu CM et al. N-Terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321-330
19. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606
20. Bart BA, Shaw LK, McCants CB Jr et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30: 1002-1008
21. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39: 210-218
22. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367
23. Charytan D, Kuntz RE, Mauri L et al. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 49: 409-416
24. DeFilippi CR, Fink JC, Nass CM et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46: 35-44
25. Murphy SW. Management of heart failure and coronary artery disease in patients with chronic kidney disease. Semin Dial 2003; 16: 165-172
26. Cataliotti A, Malatino LS, Jougasaki M et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker of ventricular remodeling. Mayo Clin Proc 2001; 76: 1111-1119
27. Osajima A, Okazaki M, Tamura M et al. Comparison of plasma levels of mature adrenomedullin and natriuretic peptide as markers of cardiac function in hemodialysis patients with coronary artery disease. Nephron 2002; 92: 832-839
28. Nishikimi T, Futoo Y, Tamano K et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001; 37: 1201-1208
29. Kragelund C, Gronning B, Kober L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666-675
30. Choi EY, Kwon HM, Yoon YW et al. Assessment of extent of myocardial ischemia in patients with non-ST elevation acute coronary syndrome using serum B-type natriuretic peptide level. Yonsei Med J 2004; 45: 255-262
31. McClure SJ, Gall S, Schechter CB et al. Percutaneous coronary revascularization reduces plasma N-terminal pro-B-type natriuretic peptide concentration in stable coronary artery disease. J Am Coll Cardiol 2007; 49: 2394-2397
32. Iwanaga Y, Kihara Y, Niizuma S et al. BNP in overweight and obese patients with heart failure: an analysis based on the BNP-LV diastolic wall stress relationship. J Card Fail 2007; 13: 663-667
33. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8: 355-358
34. Wahl HG, Graf S, Renz H et al. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071-1074
35. Clerico A, Fontana M, Zyw L et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007; 53: 813-822